

Special Issue

Role of Placenta-Derived Mesenchymal Stem Cells in Human Health and Disease

Message from the Guest Editor

The placenta is a temporary organ that regulates the exchange of nutrients, metabolites, gases, antibodies, and all that is required to establish the environment where a fetus can develop until birth. Several cell types of maternal and fetal origins contribute to accomplishing these functions. At full term, the placenta is usually discarded but it represents an abundant source of mesenchymal stromal cells (MSCs) and thus could provide cell precursors for cell therapy. In addition to their self-renewal ability, immunomodulatory properties, and plasticity, placenta-derived MSCs are neither teratogenic nor liable of ethical limitations. As compared to MSCs derived from bone marrow and from other tissues, placenta-derived MSCs remain under-investigated. Given the development of tissue engineering, cellular therapies and artificial organs, there will be an increasing need for cells endowed with plasticity and trophic properties. This Special Issue aims to collect reviews and research papers describing the functional properties and the potential of MSCs and any other aspect that may help to take advantage of this precious resource for regenerative therapies.

Guest Editor

Dr. Luca Giacomello

Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics,
University of Verona, 37134 Verona, Italy

Deadline for manuscript submissions

closed (31 July 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/175869

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).